Streetbeat News

Analyst Ratings

ALLO

EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on Allogene Therapeutics (NASDAQ:ALLO) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:04 pm

U

Credit Suisse analyst Stephen Ju has maintained an 'Outperform' rating on Unity Software (NYSE:U) but lowered the price target from $66 to $61.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:04 pm

CG

Oppenheimer analyst Chris Kotowski has maintained an 'Outperform' rating on Carlyle Group (NASDAQ:CG) but lowered the price target from $60 to $58.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:04 pm

HOOD

Citigroup analyst Christopher Allen has maintained a Neutral rating on Robinhood Markets (NASDAQ:HOOD) and raised the price target from $10 to $12.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:04 pm

MELI

Credit Suisse analyst Stephen Ju has maintained an 'Outperform' rating on MercadoLibre (NASDAQ:MELI) and raised the price target from $1760 to $1780.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:04 pm

SHOP

Shopify Inc. (NYSE:SHOP) reported better-than-expected Q2 earnings and sales results, with a 31% YoY increase in revenue to $1.69 billion. The company expects Q3 revenue to grow at a low-twenties percentage rate YoY. Following the announcement, Piper Sandler and Barclays raised their price targets on Shopify. Despite the positive results, Shopify shares fell 1.1% in pre-market trading.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 1:04 pm

CHRW

Citigroup analyst Christian Wetherbee maintains a Neutral rating on C.H. Robinson Worldwide (NASDAQ:CHRW) and raises the price target from $94 to $98.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:04 pm

CLH

Oppenheimer analyst Noah Kaye has maintained an Outperform rating on Clean Harbors (NYSE:CLH) and raised the price target from $177 to $180.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:04 pm

CFLT

Citigroup analyst Tyler Radke maintains a Neutral rating on Confluent (NASDAQ:CFLT) and raises the price target from $36 to $37.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:04 pm

VRCA

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has announced the acceptance of an abstract featuring clinical data from its ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma. The data will be presented at the 2023 American Academy of Dermatology Innovation Academy. VP-315 is a potential first-in-class oncolytic peptide immunotherapy that may offer a non-surgical option for patients suffering from skin cancer.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 1:04 pm